Get the Stockscreener App
0.7025
0.36%
0.0025
Ocugen Inc stock is traded at $0.7025, with a volume of 3.13M.
It is up +0.36% in the last 24 hours and up +1.75% over the past month.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
See More
Previous Close:
$0.70
Open:
$0.6914
24h Volume:
3.13M
Relative Volume:
0.85
Market Cap:
$208.85M
Revenue:
-
Net Income/Loss:
$-63.08M
P/E Ratio:
-2.6019
EPS:
-0.27
Net Cash Flow:
$-72.53M
1W Performance:
-1.78%
1M Performance:
+1.75%
6M Performance:
-26.68%
1Y Performance:
-61.19%
1-Day Range:
$0.671
$0.7175
1-Week Range:
$0.65
$0.735
52-Week Range:
$0.515
$2.06
Ocugen Inc Stock (OCGN) Company Profile
Name
Ocugen Inc
Sector
Industry
Phone
484-328-4701
Address
11 GREAT VALLEY PARKWAY, MALVERN, PA
Compare OCGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
0.7025 | 208.85M | 0 | -63.08M | -72.53M | -0.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.00 | 115.57B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
574.16 | 60.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
542.47 | 37.56B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.86 | 35.18B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
224.73 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
Ocugen Inc Stock (OCGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-15-24 | Initiated | Maxim Group | Buy |
| Mar-01-23 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Aug-23-22 | Initiated | Mizuho | Buy |
| Jun-15-22 | Resumed | ROTH Capital | Buy |
| Jun-02-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-26-21 | Initiated | Noble Capital Markets | Outperform |
| Jun-11-21 | Downgrade | ROTH Capital | Buy → Neutral |
| May-07-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-09-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Feb-04-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
View All
Ocugen Inc Stock (OCGN) Latest News
Ocugen stock price target cut to $7 by H.C. Wainwright - Investing.com Nigeria
Ocugen (OCGN) Price Target Reduced by H.C. Wainwright | OCGN Sto - GuruFocus
Ocugen (OCGN) Maintains 'Buy' Rating Despite Price Target Adjust - GuruFocus
Ocugen (OCGN) Receives Ongoing "Buy" Rating from Chardan Capital - GuruFocus
The Analyst Verdict: Ocugen In The Eyes Of 5 Experts - Benzinga
Ocugen outlines 2025 milestones for gene therapy programs with BLA filings on track - MSN
Ocugen, Inc. (NASDAQ:OCGN) Q1 2025 Earnings Call Transcript - Insider Monkey
Ocugen: Q1 Earnings Snapshot - San Francisco Chronicle
Ocugen Inc (OCGN) Q1 2025 Earnings Call Highlights: Strategic Advances in Gene Therapy Amid ... - Yahoo
Earnings call transcript: Ocugen’s Q1 2025 loss narrows, stock rises By Investing.com - Investing.com India
Ocugen Inc (OCGN) Q1 2025 Earnings Call Highlights: Strategic Advances in Gene Therapy Amid ... By GuruFocus - Investing.com Canada
Earnings call transcript: Ocugen’s Q1 2025 loss narrows, stock rises - Investing.com
Ocugen’s Q1 2025: Progress in Gene Therapy Trials - TipRanks
Ocugen Inc’s Earnings Call: Optimism Amid Financial Challenges - TipRanks
Ocugen Provides Business Update with First Quarter 2025 Financia - GuruFocus
Ocugen Q1 2025 Earnings Call Transcript - MarketBeat
Ocugen (OCGN) Reveals Strong Q1 Revenue Growth and Strategic Cli - GuruFocus
Ocugen Provides Business Update with First Quarter 2025 Financial Results - Ocugen
Ocugen Stock Rises On Better-Than-Feared Q1 Loss: Retail Turns Bullish By Stocktwits - Investing.com India
Ocugen Stock Rises On Better-Than-Feared Q1 Loss: Retail Turns Bullish - MSN
Ocugen (OCGN) Set to Release Q1 Earnings with Minimal Revenue Ex - GuruFocus
A Look at Ocugen's Upcoming Earnings Report - Nasdaq
Ocugen (OCGN) Set to Release Q1 Earnings with Minimal Revenue Expectations - GuruFocus
Ocugen to Host Q1 2025 Earnings Call and Business Update on May 9 - MSN
Ocugen to Showcase Gene Therapy Advances at Upcoming Ophthalmology Conferences - MSN
Ocugen to Host Conference Call on Friday, May 9 at 8:30 A.M. ET - GuruFocus
Ocugen to Host Conference Call on Friday, May 9 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2025 Financial Results | OCGN Stock News - GuruFocus
Ocugen, Inc. to Host Conference Call for Q1 2025 Financial Results and Business Update - Nasdaq
Ocugen to Host Conference Call on Friday, May 9 at 8:30 - GlobeNewswire
Ocugen to Host Conference Call on Friday, May 9 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2025 Financial Results - TradingView
Gene Therapy Pioneer Ocugen Sets Q1 2025 Earnings Call to Reveal Blindness Treatment Progress - Stock Titan
Ocugen to Present at Eyecelerator Conference May 2025 - TipRanks
Ocugen to Present on Modifier Gene Therapy Platform at Associati - GuruFocus
OCUGEN Earnings Preview: Recent $OCGN Insider Trading, Hedge Fund Activity, and More - Nasdaq
Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2025 Annual Meeting and Retina World Congress - Ocugen
Stock Quote & Chart - Ocugen
Ocugen, Inc. to Showcase Innovative Modifier Gene Therapy Platform at Upcoming ARVO and Retina World Congress Meetings - Nasdaq
Ocugen to Present on Modifier Gene Therapy Platform at - GlobeNewswire
Revolutionary Gene Therapy Platform: Ocugen Presents Phase 3 Trial Results for Multiple Eye Diseases - Stock Titan
O’Reilly Automotive: An Anytime Buy for Buy-and-Hold Investors - The Globe and Mail
Press Release Distribution & PR Platform - ACCESS Newswire
Form DEF 14A Ocugen, Inc. For: Jun 05 - StreetInsider
Ocugen, Inc. Announces Directorate Resignations - marketscreener.com
Ocugen Inc Stock (OCGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):